You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 168 No. 22, Dec 8/22, 2008 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Investigation
 •Online Features
 This Article
 •Full text
 •PDF
 •Correction
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (20)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Viral Infections
 •Public Health
 •Immunization
 •Public Health, Other
 •Women's Health
 •Women's Health, Other
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005)

Age, Dose, and Sex Effects on Immune Responses

Renata J. M. Engler, MD; Michael R. Nelson, MD, PhD; Mary M. Klote, MD; Mark J. VanRaden, PhD; Chiung-Yu Huang, PhD; Nancy J. Cox, PhD; Alexander Klimov, PhD, ScD; Wendy A. Keitel, MD; Kristin L. Nichol, MD; Warner W. Carr, MD; John J. Treanor, MD; for the Walter Reed Health Care System Influenza Vaccine Consortium

Arch Intern Med. 2008;168(22):2405-2414.

Background  Optimal public health strategies for managing influenza vaccine shortages are not yet defined. Our objective was to determine the effects of age, sex, and dose on the immunogenicity of intramuscular trivalent inactivated vaccine (TIV).

Methods  Healthy adults aged 18 to 64 years, stratified by age (18-49 and 50-64 years) and sex, were randomized to receive full- or half-dose TIV. Hemagglutination inhibition titers against vaccine antigens were measured before and 21 days after immunization. A primary outcome of noninferiority was defined as a difference of less than 20% in the upper 95% confidence interval (CI) of the proportion of subjects with strain-specific hemagglutination inhibition antibody titers of 1:40 or higher after vaccination. Secondary outcomes included geometric mean titers, after vaccination side effects, and occurrences of influenza-like illnesses.

Results  Among previously immunized subjects (N = 1114) receiving half- vs full-dose TIV (age, 18-49 years, n = 284 [half] and n = 274 [full]; and age 50-64 years, n = 276 [half] and n = 280 [full]), CIs for proportions of subjects with hemagglutination inhibition antibody titers of 1:40 or higher excluded substantial reduction for all antigens in the 18- to 49-year age group and for B/Shanghai/361/2002 (B) and A/Fujian/411/2002 (A/H3N2) in the 50- to 64-year age group. Geometric mean titer in the female 18- to 49-year age group exceeded male responses for all strains: responses to half-dose TIV that were comparable with male full-dose responses for A/New Caledonia/20/99 (A/H1N1) antigen, 25.4 (95% CI, 20.9-30.9) vs 25.6 (95% CI, 21.3-30.9); A/H3N2 antigen, 60.8 (95% CI, 50.8-72.7) vs 44.1 (95% CI, 37.6-51.8); and B antigen, 64.4 (95% CI, 53.9-76.9) vs 60.7 (95% CI, 51.4-71.7) (findings were similar for the 50- to 64-year age group). Some injection site and systemic reactions (myalgias and/or arthralgias [P < .05], headache [P < .001], and impact of fatigue [P < .05]) were significantly lower in men. The relative risk of medical visits and hospitalizations for influenza-like illnesses were similar in the half- and full-dose groups regardless of age.

Conclusions  Antibody responses to intramuscular half-dose TIV in healthy, previously immunized adults were not substantially inferior to the full-dose vaccine, particularly for ages 18 to 49 years. Significantly higher geometric mean titer responses in women were identified for all ages, regardless of dose or influenza strain. Half-dose vaccination may be an effective strategy for healthy adults younger than 50 years in the setting of an influenza vaccine shortage.

Trial Registration  clinicaltrials.gov Identifier: NCT00283283


Author Affiliations: Allergy-Immunology Department, Walter Reed Army Medical Center, Washington, DC (Drs Engler, Nelson, and Klote); National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (Drs VanRaden and Huang); Influenza Branch, Centers for Disease Control and Prevention, Atlanta, Georgia (Drs Cox and Klimov); Baylor College of Medicine, Houston, Texas (Dr Keitel); VA Medical Center and Department of Medicine, University of Minnesota Medical School, Minneapolis (Dr Nichol); Allergy and Asthma Associates of Southern California, Mission Viejo (Dr Carr); and Infectious Diseases Unit, Department of Medicine, University of Rochester, Rochester, New York (Dr Treanor).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

In This Issue of Archives of Internal Medicine
Arch Intern Med. 2008;168(22):2400.
FULL TEXT  

Half-Dose Influenza Vaccine: Stretching the Supply or Wasting It?
Ann R. Falsey
Arch Intern Med. 2008;168(22):2402-2403.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Immune Response Following H1N1pdm09 Vaccination: Differences in Antibody Repertoire and Avidity in Young Adults and Elderly Populations Stratified by Age and Gender
Khurana et al.
The Journal of Infectious Disease 2012;205:610-620.
ABSTRACT | FULL TEXT  

Immunogenicity of an Inactivated Monovalent 2009 H1N1 Influenza Vaccine in Pregnant Women
Jackson et al.
The Journal of Infectious Disease 2011;204:854-863.
ABSTRACT | FULL TEXT  

Randomized Controlled Trial of Dose Response to Influenza Vaccine in Children Aged 6 to 23 Months
Skowronski et al.
Pediatrics 2011;128:e276-e289.
ABSTRACT | FULL TEXT  

Efficacy of experimental treatments compared with standard treatments in non-inferiority trials: a meta-analysis of randomized controlled trials
Soonawala et al.
Int J Epidemiol 2010;39:1567-1581.
ABSTRACT | FULL TEXT  

Estrogen Receptors Bind to and Activate the HOXC4/HoxC4 Promoter to Potentiate HoxC4-mediated Activation-induced Cytosine Deaminase Induction, Immunoglobulin Class Switch DNA Recombination, and Somatic Hypermutation
Mai et al.
J. Biol. Chem. 2010;285:37797-37810.
ABSTRACT | FULL TEXT  

A Single Dose of Unadjuvanted Novel 2009 H1N1 Vaccine Is Immunogenic and Well Tolerated in Young and Elderly Adults
Talaat et al.
The Journal of Infectious Disease 2010;202:1327-1337.
ABSTRACT | FULL TEXT  

Immunogenicity and Safety of Intradermal Influenza Vaccination in Healthy Older Adults
Chi et al.
Clinical Infectious Diseases 2010;50:1331-1338.
ABSTRACT | FULL TEXT  

Half-Dose Influenza Vaccine: Stretching the Supply or Wasting It?
Falsey
Arch Intern Med 2008;168:2402-2403.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.